Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.53 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.48 |
| ▸ | PLK4 | O00444 | 3/20 | 0.48 |
| ▸ | FLT4 | P35916 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334259 | 0.88 | KDR (0.82) | KDRROCK2CLK4PIM1ROCK1 | |
| SCHEMBL30331758 | 0.85 | PARP10 (0.69) | KDRPARP10PARP11ROCK2CLK4 | |
| SCHEMBL30543349 | 0.84 | KDR (0.49) | KDRROCK2CLK4PIM1ROCK1 | |
| SCHEMBL30543339 | 0.84 | KDR (0.49) | KDRPARP10PARP11ROCK2CLK4 | |
| SCHEMBL30543353 | 0.83 | KDR (0.62) | KDRROCK2CLK4PIM1ROCK1 | |
| SCHEMBL30543361 | 0.83 | KDR (0.51) | KDRPARP10PARP11ROCK2CLK4 | |
| SCHEMBL30543331 | 0.82 | PIK3CD (0.49) | KDRPARP10PARP11ROCK2CLK4 | |
| SCHEMBL1334315 | 0.81 | KDR (0.79) | KDRROCK2CLK4PIM1ROCK1 | |
| SCHEMBL30543342 | 0.81 | KDR (0.51) | KDRPARP10PARP11ROCK2CLK4 | |
| SCHEMBL30543362 | 0.81 | KDR (0.49) | KDRGSTP1ROCK2CLK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496246-A | Isoindoline compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-07-28 | — | — | CN | claimed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | claimed |
| EP-1633710-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | Abbott Laboratories (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | claimed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | claimed |
| CN-116496246-A | Isoindoline compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-07-28 | — | — | CN | disclosed |
| WO-2012061602-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633710-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | Abbott Laboratories (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| WO-2004108672-A1 | ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885PARP10 1523/4885PARP11 1123/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885PARP10 1523/4885PARP11 1123/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | KDR 527/4885PARP10 1523/4885PARP11 1123/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | KDR 909/4885PARP10 879/4885PARP11 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.